天臣医疗（688013）披露2025年度业绩快报公告，2月27日股价上涨0.51%

Core Viewpoint - Tianchen Medical (688013) reported strong financial performance for the fiscal year 2025, indicating significant growth in revenue and profit metrics, which may present investment opportunities in the healthcare sector [1] Financial Performance Summary - The total operating revenue for 2025 reached 326,736,247.45 yuan, reflecting a year-on-year increase of 19.96% [1] - Operating profit amounted to 94,237,898.44 yuan, showing a substantial growth of 71.35% compared to the previous year [1] - Net profit attributable to shareholders was 84,092,590.88 yuan, which is a 62.04% increase year-on-year [1] - The net profit, excluding non-recurring gains and losses, grew by 56.53% year-on-year [1] - Basic earnings per share were reported at 1.05 yuan, with a weighted average return on equity of 14.83% [1] Asset and Equity Summary - Total assets as of the end of 2025 were 672,845,043.11 yuan, representing a growth of 5.59% from the beginning of the year [1] - Equity attributable to shareholders decreased by 2.92% from the beginning of the year, totaling 564,456,295.51 yuan [1]